Wright Medical Update on AUGMENT Reimbursement

By Julie A. Vetalice

Wright Medical Update on AUGMENT Reimbursement

Wright Medical announced that the U.S. Centers for Medicare & Medicaid Services (CMS) updated the reimbursement calculation used to determine the transitional pass-through payment for the device category applicable to AUGMENT® Bone Graft and AUGMENT® Injectable, originally implemented in January 2020.

When hindfoot and ankle fusions are performed in hospital outpatient and ambulatory surgical center settings, the facility will be paid for the incremental cost of AUGMENT, facilitating Medicare beneficiary access by removing an economic barrier.

AUGMENT is offered as an alternative to harvested autograft in ankle and hindfoot fusion.

Robert Palmisano, President and Chief Executive Officer, said, “The update to the transitional pass-through payment in the outpatient setting will help ensure healthcare providers have access to AUGMENT Regenerative Solutions, which offer a clear patient benefit by eliminating the complications of the additional surgery required to harvest autograft that can result in site-specific complications and/or prolonged harvest site pain in some patients. Wright has been dedicated to advancing the standard of care for hindfoot and ankle fusion, and we are proud that the Centers for Medicare & Medicaid Services, the country's largest payer for health care, recognizes the importance of our AUGMENT technology to its beneficiaries.”

Product Labels: Bone Graft Materials/DBM